Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Open Access Highly Accessed Research article

Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity

Maximino Redondo1*, Teresa Téllez1, Maria J Roldan1, Alfonso Serrano2, Maria García-Aranda1, Martin E Gleave3, Maria L Hortas1 and Miguel Morell2

Author Affiliations

1 Department of Biochemistry, Hospital Costa del Sol, Carretera de Cádiz Km 187, 29600 Marbella, Málaga, Spain

2 Department of Biochemistry and Immunology, Virgen de la Victoria University Hospital, Campus Universitario Teatinos, 29010 Málaga, Spain

3 Prostate Center at Vancouver General Hospital, 2660 Oak Street, Vancouver, BC V5Z 3J5, Canada

For all author emails, please log on.

Breast Cancer Research 2007, 9:R86  doi:10.1186/bcr1835

Published: 13 December 2007

Abstract

Introduction

Overexpression of the apoptosis-related protein clusterin is associated with breast cancer development and tumor progression. We describe the use of clusterin-specific antisense oligonucleotides and antibodies to sensitize breast carcinoma cells to anticancer drugs routinely used in breast cancer therapy.

Methods

MCF-7 and MDA-MB-231 cells were treated with the oligonucleotide or antibody, chemotherapeutic agents (doxorubicin or paclitaxel), tamoxifen, or with combinations of these.

Results

Treatments that include antisense clusterin oligonucleotide or antibody to clusterin have been shown to reduce the number of viable cells more effectively than treatment with the drugs alone. We also demonstrate that dexamethasone pretreatment of breast cancer cell lines inhibits chemotherapy-induced cytotoxicity and is associated with the transcriptional induction of clusterin. However, anticlusterin treatment increases chemotherapy-induced cytotoxicity, even in the presence of glucocorticoids, suggesting a possible role for these proteins in glucocorticoid-mediated survival.

Conclusion

These data suggest that combined treatment with antibodies to clusterin or antisense clusterin oligodeoxynucleotides and paclitaxel, doxorubicin, or tamoxifen could be a novel and attractive strategy to inhibit the progression of breast carcinoma by regulation of the clusterin function. Moreover, glucocorticoid activation in breast cancer cells regulates survival signaling by the direct transactivation of genes like clusterin which encode proteins that decrease susceptibility to apoptosis. Given the widespread clinical administration of dexamethasone before chemotherapy, understanding glucocorticoid-induced survival mechanisms is essential for achieving optimal therapeutic responses.